[The use of reaferon in treating patients with protracted viral hepatitis].
The paper reports the results of a randomized clinicoimmunological trial of domestic recombinant alpha 2-interferon (reaferon) in 30 patients with protracted viral hepatitis (27 subjects had viral hepatitis B and 3 patients HBV + HDV-coinfection). The reaferon treatment started on the disease week 7-8 and lasted for 2 months (1 x 10(6) IU, once a week, i.m.). VHB patients benefited from reaferon treatment as evident from improved clinical and laboratory indices, cases of complete cure and the agent elimination. In a protracted course of HBV + HDV coinfection reaferon in the above doses failed to produce any effect.
Kokoreva
L N
LN
Zmyzgova
A V
AV
Nazarenko
I V
IV
D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000628:therapy*; D003699:Hepatitis D / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D013997:Time Factors
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Primenenie reaferona v lechenii bol'nykh zatiazhnym virusnym gepatitom.